regulator of G protein signaling 4Genealiases: RGP4 · SCZD9
Q-omics provides the consensus-scored RGS4 profile across patient tissues and cancer cell-line models. RGS4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RGS4 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, RGS4 RNA expression shows 20,414 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where RGS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS4 survival associations across molecular data types. RGS4 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS4 RNA expression–survival associations across cancer types. High RGS4 expression shows unfavorable associations in KIRP, STAD, MESO, SARC, SCLC and GBM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RGS4 RNA expression.
This table summarizes RGS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RGS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS4 shows lower tumor expression in LIHC and KICH and higher tumor expression in HNSC, BRCA, LUAD and THCA. The HNSC box plot shows higher RGS4 RNA expression in tumor versus normal tissue (log2 FC = +2.032, t-test p < 0.001).
This table shows molecular features associated with RGS4 in patient tissues and cancer cell lines. In patient samples, RGS4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
